 Immunosuppressive Agents
"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 1 | 0 | 1 | | 1982 | 1 | 1 | 2 | | 1984 | 0 | 1 | 1 | | 1987 | 1 | 1 | 2 | | 1988 | 0 | 4 | 4 | | 1989 | 0 | 1 | 1 | | 1990 | 15 | 1 | 16 | | 1991 | 10 | 2 | 12 | | 1992 | 2 | 3 | 5 | | 1993 | 8 | 3 | 11 | | 1994 | 11 | 3 | 14 | | 1995 | 9 | 2 | 11 | | 1996 | 23 | 14 | 37 | | 1997 | 26 | 15 | 41 | | 1998 | 36 | 14 | 50 | | 1999 | 30 | 20 | 50 | | 2000 | 14 | 12 | 26 | | 2001 | 20 | 13 | 33 | | 2002 | 9 | 5 | 14 | | 2003 | 20 | 8 | 28 | | 2004 | 14 | 16 | 30 | | 2005 | 14 | 12 | 26 | | 2006 | 23 | 15 | 38 | | 2007 | 10 | 15 | 25 | | 2008 | 8 | 12 | 20 | | 2009 | 11 | 13 | 24 | | 2010 | 15 | 13 | 28 | | 2011 | 13 | 8 | 21 | | 2012 | 14 | 10 | 24 | | 2013 | 18 | 17 | 35 | | 2014 | 18 | 9 | 27 | | 2015 | 6 | 12 | 18 | | 2016 | 13 | 9 | 22 | | 2017 | 9 | 8 | 17 | | 2018 | 8 | 6 | 14 | | 2019 | 6 | 10 | 16 | | 2020 | 6 | 10 | 16 | | 2021 | 5 | 4 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Hamdeh S, Micic D, Hanauer S. Review article: drug-induced small bowel injury. Aliment Pharmacol Ther. 2021 12; 54(11-12):1370-1388.
-
Horton DB, Reder AT. Medications for Multiple Sclerosis and Risk of Malignancy: What Next? Neurotherapeutics. 2021 07; 18(3):1650-1653.
-
Nair A, Coromina Hernandez L, Shah S, Zervos X, Zimmerman M, Sasaki K, Diago T, Hashimoto K, Fujiki M, Aucejo F, Bollinger J, Kaiser TL, Miller CM, Quintini C, Fung JJ, Eghtesad B. Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial. Transplantation. 2022 May 01; 106(5):997-1003.
-
El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol. 2021 07 01; 37(4):313-319.
-
Buisson A, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, Fumery M, Laharie D, Roblin X, Bommelaer G, Pereira B, Peyrin-Biroulet L, Vuitton L. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.
-
Kastin D, Siegel M, Anderson R, Aronsohn A. IgG 4 Autoimmune Hepatitis Presenting as Idiopathic Hypereosinophilia Syndrome. Hepatology. 2021 04; 73(4):1615-1617.
-
Cree BA, Cohen JA, Reder AT, Tomic D, Silva D, Piani Meier D, Laflamme AK, Ritter S, Leppert D, Kappos L. Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Mult Scler. 2021 12; 27(14):2219-2231.
-
Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Bachul PJ, Golab K, Basto L, Zangan S, Pyda JS, Perez-Gutierrez A, Borek P, Wang LJ, Tibudan M, Tran DK, Anteby R, Generette GS, Chrzanowski J, Fendler W, Perea L, Jayant K, Lucander A, Thomas C, Philipson L, Millis JM, Fung J, Witkowski P. Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation. Cell Transplant. 2021 Jan-Dec; 30:9636897211001774.
-
Melmed GY, Rubin DT, McGovern DPB. Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic. Gastroenterology. 2021 02; 160(3):639-644.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|